(Q34353074)

1 August 2017

0 references

Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials (English)

1 reference

1 August 2017

0 references

0 references

1 reference

Aleman A

1

1 reference

PubMed ID

11532383

1 August 2017

Kahn RS

series ordinal

2

1 reference

PubMed ID

11532383

1 August 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

1 August 2017

5

1 reference

European Neuropsychopharmacology

inferred from page(s)

published in

1 reference

1 August 2017

11

1 reference

1 August 2017

4

1 reference

1 August 2017

289-293

1 reference

Psychotherapeutic approaches to aggressive and violent patients.

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900097-9

7 January 2021

Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900097-9

7 January 2021

Fluoxetine and impulsive aggressive behavior in personality-disordered subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900097-9

7 January 2021

Neurotransmitter correlates of impulsive aggression in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900097-9

7 January 2021

Effect of risperidone on hostility in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900097-9

7 January 2021

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900097-9

7 January 2021

Psychopharmacologic treatment of pathologic aggression

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900097-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900097-9

1 reference

7 January 2021

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900097-9

7 January 2021

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900097-9

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900097-9

7 January 2021

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900097-9

7 January 2021

Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900097-9

7 January 2021

Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900097-9

7 January 2021

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900097-9

7 January 2021

Meta-analysis programs

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900097-9

7 January 2021

Aggressive behavior against self and others among first-admission patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900097-9

7 January 2021

Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns

1 reference

https://api.crossref.org/works/10.1016%2FS0924-977X%2801%2900097-9

7 January 2021

10.1016/S0924-977X(01)00097-9

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11532383